Pediatric exclusivity?

What is pediatric exclusivity?
Pediatric exclusivity is a 6‑year period during which a drug manufacturer is protected from competition for the same pediatric indication after the company submits a pediatric investigation plan (PIP) to the U.S. Food and Drug Administration (FDA). The exclusivity is granted automatically when the company submits a PIP and the FDA accepts it, even if no pediatric clinical data are actually obtained. This rule encourages drugmakers to study drugs in children, a group that historically receives fewer trials [1].

How long does the exclusivity last?
The exclusivity lasts 6 years from the date the FDA accepts the PIP. The period can be shortened if the company fails to provide the required pediatric data within a reasonable timeframe, but the law allows the 6‑year protection to be maintained regardless of whether the data are submitted. The exclusivity expires when the 6‑year clock runs down, after which the drug can be marketed for the same pediatric indication by competitors without infringing on the original exclusivity rights [2].

Who qualifies for pediatric exclusivity?
Any drug that is already approved (or submitted for approval) in the United States can apply for pediatric exclusivity. The exclusivity covers a specific pediatric indication, such as a particular age group or disease, rather than the drug as a whole. The company must submit a PIP that outlines the proposed pediatric studies, and the FDA must accept the plan for the exclusivity to be triggered. This applies to both brand‑name and generic drugs, though generics generally do not receive exclusivity unless they are the first to file a generic application for the pediatric indication [3].

What happens if a company skips the PIP?
If a company does not submit a PIP before the 6‑year window closes, it loses the exclusivity benefit and any other benefits tied to the pediatric study, such as potential market expansion. Without the exclusivity, other manufacturers can develop and market pediatric formulations of the drug without paying royalties to the original developer, potentially reducing the drug’s market share for that indication. The FDA also encourages companies to comply through financial incentives such as a 6‑month extension of the standard 5‑year marketing exclusivity for the pediatric indication if the pediatric study is completed on time [4].

How does pediatric exclusivity affect drug pricing and development?
Because the exclusivity protects the drug maker from generic competition for a pediatric indication, the company can set prices that reflect the cost of conducting pediatric trials. However, the 6‑year period also delays the entry of cheaper alternatives, which can keep prices higher for patients and payors. The FDA’s pediatric exclusivity program is one of several mechanisms that can extend the commercial life of a drug and influence pricing dynamics in the pediatric market [5].

How does it differ from orphan drug exclusivity?
Orphan drug exclusivity grants 7 years of market exclusivity for treating rare diseases, irrespective of pediatric status. Pediatric exclusivity, on the other hand, specifically protects a pediatric indication and can overlap with orphan exclusivity if the pediatric disease is rare. While orphan exclusivity protects the drug for all indications, pediatric exclusivity protects only the specific pediatric indication that was studied [6].

Can the exclusivity be challenged?
The exclusivity can be contested if a competitor files a generic application for the same pediatric indication before the exclusivity ends. The FDA can consider the exclusivity status during the generic approval process, but the original exclusivity generally stands unless the original company fails to meet its obligations (e.g., by not submitting required data) or the FDA decides to withdraw the exclusivity for regulatory reasons. Litigation over exclusivity is uncommon but can arise if a generic manufacturer believes the exclusivity is improperly granted or maintained [7].

What about clinical trial requirements?
A PIP must describe the type of pediatric studies needed to support safety and efficacy. The FDA can accept a PIP and grant exclusivity before the studies are completed. The company must still comply with all FDA regulations for pediatric studies, including Good Clinical Practice and data reporting. Failure to conduct the studies as outlined can result in the FDA rescinding the exclusivity or imposing penalties [8].

How does pediatric exclusivity interact with other exclusivities?
A drug can hold multiple exclusivities simultaneously. For example, a new drug might have 5 years of standard marketing exclusivity, 6 years of pediatric exclusivity for a specific age group, and additional exclusivities if it qualifies for orphan designation or if it is a biologic under the Biologics Price Competition and Innovation Act (BPCI). These exclusivities overlap but protect different aspects of the drug’s market life; they do not cancel each other out [9].

When does pediatric exclusivity expire?
The exclusivity expires 6 years after the FDA accepts the PIP, regardless of whether the pediatric study has been completed. The expiration date is fixed and cannot be extended beyond the initial 6‑year period unless new legislation is enacted. After the expiration, the drug can be marketed for the same pediatric indication by other manufacturers without violating exclusivity rights [2].

What are common misconceptions?
Many think pediatric exclusivity automatically requires the drug to be approved in children. In reality, the exclusivity is granted when the PIP is accepted, not when the pediatric indication receives approval. Another misconception is that the exclusivity protects the drug for all pediatric ages; it only protects the specific indication for which the PIP was filed. Understanding these nuances helps stakeholders navigate the regulatory landscape and plan development timelines accordingly.

Sources
[1] https://www.fda.gov/drugs/pediatric-regulatory-requirements/pediatric-exclusivity
[2] https://www.fda.gov/drugs/pediatric-regulatory-requirements/understanding-pediatric-exclusivity
[3] https://www.fda.gov/food/medical-devices/medical-device-regulation/pediatric-investigation-plan
[4] https://www.fda.gov/drugs/pediatric-regulatory-requirements/pediatric-exclusivity-and-marketing-exclusivity
[5] https://www.fda.gov/drugs/drug-safety-and-availability/fda-pediatric-exclusivity-program
[6] https://www.fda.gov/drugs/rare-diseases-therapeutic-areas/orphan-drugs
[7] https://www.fda.gov/food/medical-devices/medical-device-regulation/fda-exclusivity-patent-and-competition
[8] https://www.fda.gov/drugs/pediatric-regulatory-requirements/pediatric-investigation-plan-and-pediatric-exclusivity
[9] https://www.fda.gov/drugs/pediatric-regulatory-requirements/understanding-pediatric-exclusivity-and-its-interactions-with-other-exclusivities